Comorbidities and the willingness to pay for health improvements

Journal of Public Economics

Volumn 87, Issue 11, 2003, Pages 2399-2406

  Bleichrodt, Han ^a   Crainich, David ^b   Eeckhoudt, Louis ^c,d  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b FACULTÉS UNIVERSITAIRES SAINT LOUIS   (Belgium)

^c Mons TCTS   (Belgium)

^d Gastroenterology Department   (France)

Author keywords

Cost benefit analysis; Risk aversion, health; Willingness to pay

Indexed keywords

EID: 0141544962     PISSN: 00472727     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0047-2727(02)00047-6     Document Type: Article

References (19)

1. Carthy T. Chilton S. Covey J. Hopkins L. Jones-Lee M. Loomes G. Pidgeon N. Spencer A. On the contingent valuation of safety and the safety of contingent valuation: Part 2-The CV/SG 'chained' approach Journal of Risk and Uncertainty 17 1999 187-213
2. Coebergh J.W. Janssen M. Post P. Razenberg P. Serious comorbidity among unselected cancer patients newly diagnosed in the southeastern part of the Netherlands in 93-96 Journal of Clinical Epidemiology 52 1999 1131-1136
3. Cropper M.L. Aydede S. Portney P. Preferences for life saving programs: how the public discounts time and age Journal of Risk and Uncertainty 8 1994 243-265
4. Doherty N. Schlesinger H. Optimal insurance in incomplete markets Journal of Political Economy 91 1983 1045-1054
5. Dow W. Philipson T. Sala-i-Martin X. Longevity complementarities under competing risk American Economic Review 89 1999 1358-1371
6. Dreze J. L'utilité sociale d'une vie humaine Revue Française de Recherche Opérationnelle 6 1962 93-118
7. Evans W.N. Viscusi W.K. Estimation of state-dependent utility functions using survey data Review of Economics and Statistics 73 1991 94-104
8. Fryback D. Lawrence W. Dollars may not buy as many QALYS as we think Medical Decision Making 17 1997 276-284
9. Hammitt J.K. Valuing mortality risk: theory and practice Environmental Science and Technology 34 2000 1396-1400
10. Harris R. Nease R. The importance of patient preferences for comorbidities in cost effectiveness analyses Journal of Health Economics 16 1997 113-120
11. Johannesson M. Johansson P.O. Is the valuation of a QALY gained independent of age? Some empirical evidence Journal of Health Economics 16 1997 589-599
12. Johansson P.O. Evaluating Health Risks, an Economic Approach 1995 190 Cambridge University Press
13. Jones-Lee M. The value of changes in the probability of death or injury Journal of Political Economy 80 1974 623-648
14. O'Conor R.M. Blomquist G.C. Measurement of consumer-patient preferences using a hybrid contingent valuation method Journal of Health Economics 16 1997 667-683
15. Shepard D.S. Zeckhauser R.J. Survival versus consumption Management Science 30 1984 423-439
16. Sloan F.A. Viscusi W.K. Chesson H.W. Conover C.J. Whetten-Goldstein K. Alternative approaches to valuing intangible health losses: the evidence of multiple sclerosis Journal of Health Economics 17 1998 475-482
17. Viscusi W.K. Evans W. Utility functions that depend on health status: estimates and economic implications American Economic Review 80 1990 353-374
18. Viscusi W.K. Magat W. Huber J. An investigation of the rationality of consumer valuations of multiple health risks Rand Journal of Economics 18 1987 465-479
19. Zweifel P. Breyer F. Health Economics 1997 382 Oxford University Press